Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review

Myriam Drysdale, Mehmet Berktas, Daniel C. Gibbons, Catherine Rolland, Louis Lavoie, Emily J. Lloyd
doi: https://doi.org/10.1101/2023.12.04.23299370

Article Information

doi 
https://doi.org/10.1101/2023.12.04.23299370
History 
  • December 4, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Myriam Drysdale1,*,
  2. Mehmet Berktas1,
  3. Daniel C. Gibbons1,
  4. Catherine Rolland2,
  5. Louis Lavoie3 and
  6. Emily J. Lloyd1
  1. 1Value Evidence and Outcomes, GSK, Middlesex, UK
  2. 2Evidence Synthesis, Modelling and Communications, PPD Evidera, London, UK
  3. 3Evidence Synthesis, Modelling and Communications, PPD Evidera, Montreal, Canada
  1. ↵*Corresponding author:
    Myriam Drysdale, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS. Email: myriam.g.drysdale{at}gsk.com
Back to top
Posted December 04, 2023.
Download PDF

Supplementary Material

Email
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Myriam Drysdale, Mehmet Berktas, Daniel C. Gibbons, Catherine Rolland, Louis Lavoie, Emily J. Lloyd
medRxiv 2023.12.04.23299370; doi: https://doi.org/10.1101/2023.12.04.23299370
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area